CAR-T cell therapy for glioblastoma (GBM) targets several antigens, including interleukin-13 receptor α2 (IL13Rα2), human epidermal growth factor receptor 2 (HER2), epidermal growth factor variant III (EGFRvIII), and erythropoietin-producing hepatocellular carcinoma A2 (EphA2) (18, 54). Here, ERBB2 is linked to glioblastoma.